Status:
COMPLETED
Targeting Investigation and Treatment in Patients With Type 2 Myocardial Infarction
Lead Sponsor:
University of Edinburgh
Collaborating Sponsors:
Chief Scientist Office of the Scottish Government
Conditions:
Myocardial Infarction Type 2
Eligibility:
All Genders
30+ years
Phase:
NA
Brief Summary
Type 2 myocardial infarction (MI) is common and associated with poor clinical outcomes, with as many as one in ten experiencing recurrent MI within one year, and only one in three alive at five years....
Detailed Description
TARGET-Type 2 is the pilot phase of a prospective, randomised, open label with blinded endpoint evaluation (PROBE) parallel group, event driven, multicentre trial, assessing the impact of a complex in...
Eligibility Criteria
Inclusion
- Adult patients with a clinical diagnosis of type 2 myocardial infarction, defined as:
- i. Symptoms of myocardial ischaemia, or signs of myocardial ischaemia on 12-lead electrocardiogram (≥0.5mm ST segment depression in any two contiguous leads or new regional T wave inversion)
- ii. A clinically significant change in high-sensitivity cardiac troponin concentration with at least one value above the 99th centile upper reference limit, or a single measurement if considered significantly elevated
- iii. Documented evidence of myocardial oxygen supply (anaemia, hypoxia, hypotension, bradycardia, tachycardia, arrhythmia) or demand (hypertension, left ventricular hypertrophy, valvular heart disease) imbalance.
Exclusion
- i. Patients under 30 years who are less likely to benefit from cardiac imaging
- ii. Inability to give informed consent
- iii. Patients on renal replacement therapy or with eGFR \<30ml/min
- iv. Patients with advanced frailty (based on Clinical Frailty Score ≥7)
- v. Patients who are pregnant or breast feeding
- vi. Patients with ST-segment elevation on 12-lead electrocardiogram
- vii. Patients with a clinical diagnosis of type 1 myocardial infarction
- viii. Patients who have had diagnostic imaging confirming coronary vasospasm, embolism or spontaneous coronary artery dissection has caused type 2 myocardial infarction
- ix. Previous randomization into TARGET-Type 2 pilot study
Key Trial Info
Start Date :
November 14 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05419583
Start Date
November 14 2022
End Date
June 30 2024
Last Update
September 19 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Victoria Hospital
Kirkcaldy, Fife, United Kingdom, KY25AH
2
NHS Lothian
Edinburgh, Lothian, United Kingdom, EH16 4SB